A pleasant weekend to you, myeloma world.

Today is a quiet day in terms of new myeloma-related research and news. We've got just two items in our daily list of new myeloma research, which you can always find at the end of every Myeloma Morning. The article's in today's list are specialized enough that we won't be summarizing them in this report.

We do want to mention, however, that the 2016 annual meeting of the American Association for Cancer Research (AACR) is taking place this weekend and early next …

Hello again, myeloma world.

As we continue catching up after the recent onslaught of new myeloma-related research, we're pleased to report that it's a sunny spring day outside. More importantly, our top story today reflects Mother Nature's pleasant disposition.

In particular, there is updated data about multiple myeloma survival in the United States, and it's good news.

It's just an annual update – a single new value for survival five-years from the time of diagnosis. And it's for patients diagnosed all the way back in 2008 – the most recent year for …

Hello, myeloma world. It's too late to wish you a good morning, but we do hope you had a nice day.

We were right on the mark yesterday when we worried about a “tidal wave” of new myeloma-related research hitting sometime soon. The wave has hit. Today's list of new research studies – see the bottom of this article – may be longer than it's ever been.

Processing that list has taken quite a bit of time, and we won't even try to cover all of the studies in today's report. Instead, …

Good morning, myeloma world.

Have you ever gone for a walk on a hot summer day, with birds singing and insects buzzing and the sound of children and traffic in the distance, and all of a sudden you notice that all of the sounds that were there before aren't there any more, and it's really, really quiet? Like, scary quiet?

Well, that's how we feel right now here at Myeloma Morning Headquarters, be­cause we don't have a single new myeloma-related research study or business news item to report about.

Nada. Zilch. Zero. …

Good morning, myeloma world.

It's another rainy day here at Myeloma Morning Headquarters, and we're trying to stay positive by keeping in mind that old rhyme, “April showers bring May flowers.”

“Rain is good,” we keep telling ourselves. “Rain is good.”

But we're not so sure, so we're turning our attention to our main task today, which is getting you up to speed on what's new in myeloma world.

In that regard, we'll be focusing first on a brief study by myeloma special­ists at the Mayo Clinic. They've investigated the treatment and …

Good morning, myeloma world.

It's Monday, and the weekend definitely is over. The vigorous activity in our email inbox is making that eminently clear. But, with the week still so young, there isn't much new myeloma research for us to review with you. In fact, we have just two new studies that we'd like to discuss today.

Both studies are by European researchers who have compiled and analyzed retrospective data on some important topics.

One study out of Portugal looks at the use of Revlimid (lenalidomide) to treat multiple myeloma patients who …

Good morning, myeloma world.

It's a Sunday, so it probably won't be too much of a surprise that today's list of new multiple myeloma-related research is rather short.

In fact, a quick check of our usual list of new multiple myeloma research – which we include at the end of every edition of Myeloma Morning – reveals that there are just three new studies.

We'll spend most of our time in today's report looking at a European study published on Friday. It investigates the genetics of peripheral neuropathy in …